{"entity":{"id":"clasp-therapeutics","kind":"company","name":"Clasp Therapeutics","aka":[],"tldr":"Clasp Therapeutics makes off-the-shelf T cell engagers that recognise fragments of mutated cancer proteins, such as mutant p53 and KRAS, shown on the surface of tumour cells. Its first medicine, for cancers with a specific p53 mutation, has been in a phase 1 trial since 2025.","summary":"Clasp Therapeutics, co-founded by Bert Vogelstein and Drew Pardoll of Johns Hopkins University, launched on 20 March 2024 with a USD 150 million Series A led by Catalio Capital Management, Third Rock Ventures and Novo Holdings. Its pHLAre molecules are bispecific T cell engagers that bind a mutant peptide presented by a particular HLA type on cancer cells and recruit T cells to kill them, reaching driver mutations inside the cell that conventional antibodies cannot. The lead CLSP-1025 targets the p53 R175H mutant peptide on HLA-A*02:01 and dosed its first patient in the phase 1 GUARDIAN-101 trial (NCT06778863) in April 2025, with data presented at ESMO 2025. CLSP-5282, a T cell engager against the KRAS G12V peptide on HLA-A*03:01, was unveiled at AACR 2026. The company is based in Cambridge, Massachusetts, with a site in Rockville, Maryland.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.clasptx.com/"},{"label":"Launch and USD 150 million Series A, March 2024","url":"https://www.clasptx.com/press-release-publications/clasp-therapeutics-launches-with-150-million-to-pioneer-precision-immuno-oncology-using-next-generation-t-cell-engagers-with-unparalleled-specificity"},{"label":"GUARDIAN-101 data at ESMO 2025","url":"https://www.clasptx.com/press-release-publications/esmo2025"},{"label":"CLSP-5282 at AACR 2026","url":"https://www.clasptx.com/press-release-publications/clasp-therapeutics-unveils-first-in-class-kras-t-cell-engager-clsp-5282-at-aacr-2026"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["tp53","kras","cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06778863"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the company launched publicly on 20 March 2024. Only patients whose tumours carry the exact mutation and HLA type can be eligible for each molecule."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.clasptx.com/","stage":"startup","investors":["third-rock-ventures","novo-holdings","acs-brightedge","alexandria-venture-investments"],"funding":[{"round":"Series A","year":2024,"amountUsd":150000000,"source":"https://www.clasptx.com/press-release-publications/clasp-therapeutics-launches-with-150-million-to-pioneer-precision-immuno-oncology-using-next-generation-t-cell-engagers-with-unparalleled-specificity","note":"Led by Catalio Capital Management, Third Rock Ventures and Novo Holdings"}]},"route":"/companies/clasp-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"trial":[{"id":"nct06778863","kind":"trial","name":"CLSP-1025 in p53 R175H solid tumors","route":"/trials/nct06778863/"}],"company":[{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/"},{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}